Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor and Venetoclax Maintenance in AML/MDS Post-Transplant
NCT06765928Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jan 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), sponsored by Ruijin Hospital. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
selinexor
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndromes (MDS)
Beyond the preview
Go deeper on NCT06765928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06765928.